Bank of New York Mellon Corp Reduces Investment in Medpace Holdings, Inc.

As of the fourth quarter of 2025, Bank of New York Mellon Corp has reduced its shareholding in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.1%. This information comes from the company's latest Form 13F filing with the Securities and Exchange Commission. After selling 2,308 shares during the quarter, the fund now owns 199,981 shares of Medpace, representing approximately 0.64% of the company and valued at $66,440,000.

Other institutional investors have also been active regarding their positions in Medpace. For example, Cabot Wealth Management Inc. increased its stake by 5.6% during the same quarter and now holds 16,496 shares valued at $5,480,000 after acquiring an additional 871 shares. Additionally, Arcadia Investment Management Corp MI initiated a new position in Medpace, estimated at $72,000, while Prakash Investment Advisors LLC also bought newly valued shares worth $571,000. O Brien Greene & Co. Inc. made a new investment estimated at $4,265,000, and Ieq Capital LLC expanded its holdings by a significant 1,090.6% during the quarter, bringing its total to 27,206 shares worth about $9,039,000. Overall, institutional investors now own 77.98% of Medpace's stock.

Analyst Ratings

In recent analyst ratings, Robert W. Baird has raised their price target for Medpace from $354.00 to $362.00 and maintained a “neutral” rating on the stock as of January 27th. Currently, seven analysts have given Medpace a hold rating, while five analysts recommend buying the stock. According to MarketBeat.com, Medpace has an average rating of “Hold” and a consensus price target of $381.44.

Stock Performance

On Tuesday, Medpace's stock opened at $319.17. The company's 50-day and 200-day simple moving averages stand at $342.26 and $344.70, respectively. Medpace Holdings, Inc. has seen a 52-week low of $302.01 and a high of $459.77. The stock has a market capitalization of $9.72 billion, with a price-to-earnings (P/E) ratio of 25.27 and a PEG ratio of 3.81. The stock's beta is recorded at 1.36.

Recently, Medpace reported its quarterly earnings on February 10th, where it exceeded analyst expectations by posting an EPS of $3.67, surpassing the consensus estimate of $2.96 by $0.71. The company demonstrated a strong return on equity of 51.48% and achieved a net margin of 19.17%. Analysts expect Medpace Holdings, Inc. to report earnings of 12.29 per share for the current year.

About Medpace Holdings, Inc.

Medpace Holdings, Inc. provides outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. Its comprehensive services include clinical trial management, data-driven feasibility studies, regulatory affairs, patient recruitment, and more.

Investment, Shares, Stocks